BioInitials, incorporated in April 2019, develops non-invasive medical devices to monitor the health-state of the oral cavity. Our goal is to increase the degree of oral health among the general population, to prevent periodontitis, diabetes and cardiovascular diseases.
Periodontitis is a significant public health problem with prevalence higher than 50%. In the USA and Europe, the disease affects more than 220 million patients. The disease that affects 700 million patients worldwide, is correlated to Diabetes. Cardiovascular diseases are the number one cause of death globally, with a prevalence of 422 million patients and taking an estimated 18 million lives each year.
According to the WHO, the world spent US$ 7.5 trillion on health in 2016, representing close to 10% of global GDP. Prevention accounts for only 12% of total health spending, while 72% of the costs are associated with inpatient and outpatient care and the respective medication.
Early diagnosis and prevention of chronical diseases such as periodontitis will reduce the treatment costs. Also the incidence of its associated systemic diseases. The financial impact on the health-care systems will be significant.
Periodontitis is a set of inflammatory conditions that affects the oral tissues. In its early stage it is called gingivitis – gums get swollen and bleed. Late-stage periodontitis results in bone and tooth loss. At an early stage of the disease the costs of treatment are relatively low. Left untreated restorative procedures with crowns based on bridges or implants are necessary.
Diabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels of insulin, a hormone responsible for regulating blood sugar. Epidemiological data confirms that diabetes is a major risk factor for periodontitis. Compared to the general population the likelihood of getting periodontitis is threefold higher in people with diabetes. Diabetic individuals with a severe form of periodontal disease have 3.2 times greater mortality risk than individuals with no or mild periodontitis.
Cardiovascular diseases are a group of disorders of the heart and blood vessels, including coronary heart disease. Heart attacks and strokes are usually acute events that are mainly caused by a blockage which prevents blood from flowing to the heart or brain. Heart attacks and strokes are usually caused by a combination of risk factors, including: tobacco use, unhealthy diets, obesity, hypertension and diabetes.
Salivary biomarkers play a key role in the early diagnosis of a number of chronic diseases such as periodontitis, diabetes and cardiovascular diseases. As a diagnostic fluid, saliva offers several advantages over serum.
Saliva offers a cost-effective approach with real-time diagnostic values: easily obtained multiple samples, no additional manipulation during the diagnostic procedure, noninvasive collection method with minimal risk of infection, addressing all categories of patients, especially those to whom blood sampling could be a challenge – children, anxious or uncooperative patients.
The demand for saliva collection devices and diagnostics is gaining substantial momentum. The market is forecasted to create revenues reaching USD 2.6 bn by the end of 2022 based on an average annual growth rate of 10%.
The founders of BioInitials GmbH are seasoned professionals active in the life sciences industry. They combine a total cumulative experience of 108 man-years of bringing drug products and medical devices to market, from ideation to final market approval.
Christoph SchäferManaging Partner | MBA of University of Basel, CEO of CIS Pharma AG. Christoph has developed and brought to market drugs, medical devices and consumer products, mainly in Ophthalmology. He was working with practitioners as a sales rep in the USA and has marketing experience in Life Sciences. Managing innovation, he has a vast experience from ideation with users to approval of products in the market.
Stefan StübingerPartner | Dentist and oral surgeon. Habilitation (assistant professorship) in experimental implantology and oral surgery at the University of Zurich. Stefan holds various patents and is initiator and co-founder of numerous spin-off companies. In several multi-disciplinary and ongoing research projects he is involved in the development of a new standard to evaluate and monitor individual risk factors related to different diseases, based on the evaluation of body fluids. Stefan’s major aim and vision is to go off from delayed reactive medical services to evidence-based predictive, preventive and personalized medicine (3P) with comparing historical baseline data unique to each wearer.
Fabio CirilloPartner | Chemist FH, CEO of Avanti Europe AG. Fabio has developed and successfully introduced to the global market several drug delivery devices, medical devices and drug manufacturing processes in diverse indications and use environments. Having worked with big pharma/biotech and big medical device, Fabio has founded Avanti Europe AG, a consulting and contracting company in the field of combination products, medical devices and pharmaceuticals. With Avanti Europe AG, Fabio supports all sizes of companies from idea to market (and beyond) in their development projects of novel, connected and fully digital products.
Christian JäggiPartner | PhD in economics of the University of Basel. Christian has experience in the pharmaceutical industry i.a. as Assistant to the Roche President Fritz Gerber. He was CEO of a pharma marketing agency. As founder of the IMK Institute for Medicine and Communication he worked for many Swiss medical associations. During the startup phase of Retrieval AG in the mid-nineties he was involved in the first digitalization/network project in Switzerland for physicians. With Jäggi Communications he edited and published several medical periodicals but was also engaged in the logistics industry (Danzas/DHL/Deutsche Post) and worked for engineering and IT companies. He is co-founder and MOB of Prosalix AG. He is member of the Swiss Association of Science Journalism.
Stefan SchaffnerPartner | Process Engineer FH/MBA. Stefan has a solid background in pharmaceutical engineering and measuring technology for hygienic applications. He accrued vast experience in different management positions in the fields of business development, innovation, product management, marketing and communication in industries such as energy, real estate and mobility.
Saso JezernikAdvisor | PhD, was educated and has conducted research at multiple universities including ETHZ, MIT (Schools of Eng. and Sloan School of Management), and Harvard. He has more than 20 y. of experience in the areas of medical and pharma innovation (new product development based on new technologies: comprising mechatronics/robotics, HW, SW, AI/ML, and wireless connectivity). In the life-science area, examples of Sašo 's work comprise development of next generation insulin pumps and medical injectors, combination devices, development of an automated drug reconstitution device, development of the next generation BT-LE connected inhaler, and wireless dental root-canal treatment biofeedback device. Saso brings with himself an extensive experience in the areas of Systems Eng., Modern SW and Cloud Systems, Quality (QMS & QA), Risk Management, and Regulatory Affairs (CE/FDA approvals).
Get in touch
4105 Biel-Benken BL